Mario Leporace | Personalized Medicine | Best Innovation Award

Posted on by sciencefather

Mario Leporace | Personalized Medicine | Best Innovation Award

Prof. Dr. Mario Leporace, Hospital and University, Italy

Prof. Dr. Mario Leporace is a distinguished Clinical Radiologist at the Department of Nuclear Medicine and Theragnostics, “Mariano Santo” Hospital, Cosenza, Italy. With expertise in oncologic imaging, hybrid and molecular imaging, and cardiovascular radiology, he is renowned for his advanced diagnostic work using X-ray, CT, MRI, PET/CT, and SPECT/CT. He holds a Master’s in Interventional Oncology and has contributed to over 15 peer-reviewed publications. His professional journey spans top institutions in Rome and Cosenza, marking a career dedicated to innovation in radiology and nuclear medicine.

Publication Profile

Scopus

Education

Prof. Dr. Mario Leporace 🎓 is a distinguished expert in interventional oncology and radiology. In 2022, he earned a Master’s Degree in Interventional Oncology from Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, with a thesis on thermal ablation of bone metastases 🔥🦴. From 2001 to 2005, he completed his post-graduate certification in Radiology at the University of Rome “Tor Vergata” 🏥, graduating cum laude with a thesis on hybrid imaging 🧠📸. He also obtained his Degree in Medicine and Surgery from the same university (1995–2001), graduating with top honors and a thesis in vascular imaging 🫀🧬.

Experience

Prof. Dr. Mario Leporace 🩺 has an extensive career in radiology and nuclear medicine, showcasing over two decades of dedicated medical service. Since October 2017, he has been serving in the Department of Nuclear Medicine and Theragnostics at “Mariano Santo” Hospital in Cosenza, Italy ⚛️🏥. From May 2016 to September 2017, he worked at the Department of Radiology, “Annunziata” Hospital 🏨. Earlier, from March 2006 to April 2016, he contributed to the European Hospital in Rome, and concurrently, from November 2005 to April 2016, served at the Aurelia Hospital in Rome 🏛️🔬, strengthening his clinical expertise across institutions.

Research Focus

Prof. Dr. Mario Leporace focuses his research on Thermal Ablation with Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) 🔬🧠. His work bridges medical physics and oncological applications, exploring non-invasive treatments that use focused ultrasound energy to thermally ablate tumors with MRI precision guidance 🎯. This technique offers cutting-edge therapeutic possibilities in fields such as oncology, neurology, and women’s health 🧬💡. Prof. Leporace’s contributions advance both the clinical outcomes and technological innovation of MRgFUS, making him a key figure in image-guided therapy, minimally invasive surgery, and cancer treatment research .

Publication Top Notes

The Thermal Ablation with MRgFUS: From Physics to Oncological Applications

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Posted on by sciencefather

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Pilar Hernandez Jimenez | Personalized Medicine | Women Researcher Award

Posted on by sciencefather

Pilar Hernandez Jimenez | Personalized Medicine | Women Researcher Award

Dr. Pilar Hernandez Jimenez, Hospital Universitario 12 de Octubre, Spain

Dr. María del Pilar Hernández Jiménez 🩺🔬 is a specialist in internal medicine with a focus on infectious diseases. She earned her M.D. from the Universidad de Alcalá (2011) and completed her MIR in Internal Medicine at HU 12 de Octubre (2013-2018). With expertise in HIV, tropical diseases, and antimicrobial resistance, she has contributed to multiple research projects, publishing 21 indexed articles (h-index 9). Currently, she is a Río Hortega researcher at Instituto de Salud Carlos III and a consultant at HU 12 de Octubre. Her doctoral thesis (2024) explores multidrug-resistant Pseudomonas aeruginosa.

Publication Profile

orcid

Education

Dr. Pilar Hernandez Jimenez 🎓 earned her Ph.D. in Health Sciences (2024) from Universidad Complutense de Madrid. She holds a Master’s in Infectious Diseases in Immunocompromised Patients 🦠 and has pursued multiple postgraduate specializations in infectious diseases, tropical medicine 🌍, and HIV 🏥. Her expertise spans critical areas of global health, focusing on combating infectious diseases and improving patient outcomes. With a strong academic foundation and extensive clinical knowledge, Dr. Hernandez Jimenez is dedicated to advancing research and medical practices in infectious disease management, contributing significantly to the field of immunocompromised patient care.

Experience

Dr. Pilar Hernandez Jimenez 🏥 currently serves at Instituto de Salud Carlos III and Hospital Universitario 12 de Octubre, where she plays a vital role in infectious disease research and hospital consultations. With extensive experience in leading studies on infectious diseases 🦠, she has contributed significantly to COVID-19 research 🦠, HIV studies 🏳️‍🌈, and infection management in immunocompromised patients 🤝. Her work bridges clinical practice and research, enhancing patient care and public health strategies. Through collaboration with top medical institutions, Dr. Hernandez Jimenez continues to make a meaningful impact on global health and infectious disease management.

International Exposure

Dr. Pilar Hernandez Jimenez 🌍 has gained extensive international exposure through Erasmus and MIR training in Spain 🇪🇸 and France 🇫🇷, enriching her expertise in infectious diseases. Her global collaborations extend to Brazil 🇧🇷, where she conducted research at Fundação de Medicina Tropical Doutor Heitor Vieira Dourado 🦠, contributing to advancements in tropical medicine and infectious disease management. These international experiences have allowed her to engage with diverse healthcare systems, collaborate with leading researchers, and enhance her medical practice on a global scale. Dr. Hernandez Jimenez continues to foster cross-border medical innovation and research excellence.

Research Focus

Dr. María del Pilar Hernández-Jiménez is a distinguished infectious disease researcher 🦠 specializing in prosthetic joint infections, multidrug-resistant bacteria, and antimicrobial treatments 💊. Her research focuses on periprosthetic infections, Pseudomonas aeruginosa, carbapenemase-producing Klebsiella pneumoniae, and infections in immunocompromised and transplant patients 🏥. She has contributed significantly to clinical microbiology, antimicrobial resistance, and infection control 📊. Dr. Hernández-Jiménez’s work extends to COVID-19-related infections and innovative treatments for latent tuberculosis in transplant recipients 🌍. Her extensive collaborations and impactful publications highlight her global influence in infectious disease research 🔬.

Publication Top Notes

Periprosthetic Infection of Transfibular Ankle Arthroplasties Managed with Implant Retention: Anatomical Limitations of Surgical Debridement

Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review

Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection

Enhancing screening adherence for strongyloides infection in latinx inpatients with COVID-19: a local protocol implementation study.